Navigation Links
New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
Date:5/16/2008

resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.

Editors' Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com

Media Contacts:

Jennifer Snyder Karen Gobler

(617) 444-1439 (617) 444-1392


'/>"/>
SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
2. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
3. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
4. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
5. More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
6. Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
7. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
8. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
9. Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
10. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
11. Supportive Oncology Services Accrues One Million Cancer Patient Self-Reported Assessments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
(Date:12/24/2014)... 2014 Echo Therapeutics, Inc. (NASDAQ: ... on skin permeation, continuous glucose monitoring and associated ... has been appointed Chief Executive Officer effective ... 20 years of experience in the medical device, ... served as Vice President, Business Development, Otsuka Pharmaceuticals as ...
(Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... Third Quarter 2007, HAYWARD, Calif., June 04, ... from a dose-escalating,Phase 1b clinical trial of ... with bortezomib (Velcade(R)), showing a,high degree of ... myeloma who had previously progressed following treatment,with ...
... NASDAQ: CRME TSX: COM, VANCOUVER and DEERFIELD, ... Corp. and its,co-development partner Astellas Pharma US, ... completed Phase 3 clinical,study, called ACT 2. ... of,the intravenous formulation of vernakalant hydrochloride,("vernakalant (iv)") ...
Cached Medicine Technology:Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO 2Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO 3Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO 4Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO 5Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing,Promising Antitumor Activity in Multiple Myeloma at ASCO 6Cardiome And Astellas Announce Positive Results From ACT 2 Trial 2Cardiome And Astellas Announce Positive Results From ACT 2 Trial 3Cardiome And Astellas Announce Positive Results From ACT 2 Trial 4Cardiome And Astellas Announce Positive Results From ACT 2 Trial 5Cardiome And Astellas Announce Positive Results From ACT 2 Trial 6
(Date:12/26/2014)... Abilene, Texas (PRWEB) December 26, 2014 Yisrayl ... has written an open letter in light of the Ferguson, ... year history of civil unrest and explains why it has ... the reason mankind was even created. He says there is ... in detail. Yisrayl also says there is a set of ...
(Date:12/26/2014)... 2014 “Many people become overwhelmed by ... claim issues and phone calls with insurance companies,” The ... featuring their free eBook on pedestrian and bicycle ... pedestrian and bicycle auto accident claims assures the injured ... of professionally handling their case while they focus on ...
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a ... producing and marketing of a series of induction heating ... new series of induction brazing equipments . , ... induction brazing refers to the joining of two ... heat. The manager says that there are fundamental differences ...
(Date:12/25/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... This report provides a basic overview of the industry ... part, the report presents the company profile, product specifications, ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. TS-1 is an anti-cancer drug which is ... orally and is also used for treating gastric cancer ... and otastat potassium. The drug was first approved in ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... According to a recent Washington Post study, approximately 20% ... psychologically damaged. Among them are a substantial number with ... suicide among PTSD sufferers has become unacceptable to Army ... research from Tel Aviv University, however, doctors will now ...
... , , , ... NEW YORK, Sept. 2 Today, Tim Gunn, television host and ... officer of Liz Claiborne, Inc., is hosting the Ad dressing Psoriasis(TM) ... fashion show recognizes people with moderate to severe plaque psoriasis who have ...
... fibrillation patients drink lots of coffee, don,t eat right, ... People who drink lots of coffee but who don,t ... atrial fibrillation, a new study shows. , Italian researchers ... heart arrhythmia to supply information about their dietary habits, ...
... , , , ... FTER), which, through its ABTTC Inc. division, provides drug and ... with the highest levels of accreditation, announced today that its ... Gaskin on the Company,s recent successes, management team and shareholder ...
... Fla., Sept. 2 Cinergy Health, a nationwide provider of Limited ... chief medical director. As Cinergy Health,s chief medical director, Dr. Lewin ... studies and emerging research to the doctor patient relationship and health ... have Dr. Lewin join the Cinergy Health team," said Daniel Touizer, ...
... , INDIANAPOLIS, Sept. 2 Eli Lilly and Company ... given the Epsilon "Star of Highest Magnitude" Award and has been ... Data Processing Associates (BDPA) and WorkplaceDiversity.com. The Epsilon Award is ... a workplace and environment that supports the advancement of African-Americans in ...
Cached Medicine News:Health News:Keeping the suicidal soldier alive 2Health News:Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis 2Health News:Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis 3Health News:Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis 4Health News:Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis 5Health News:Caffeine Without Healthy Diet Linked to Heart Risk 2Health News:Forterus Inc. Treatment Centers Showing Consistent, Sustainable Growth; CEO Paul Howarth Interviewed 2Health News:Cinergy Health Names Dr. Margaret Lewin Chief Medical Director 2Health News:Lilly Named Best Company for Blacks in Technology 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: